TRANSFORMATIVE MEDICINES
FOR CHRONIC AUTOIMMUNE
AND INFLAMMATORY DISEASES
![](/assets/images/link.png)
Late breaking news presentation slides
EADV 2024
Mission
Legacy Healthcare is developing transformative medicines for the treatment of autoimmune and inflammatory diseases, with an immune-sparing mode of action, allowing safe chronic use.
Our first drug, Coacillium, achieves this goal.
Coacillium cutaneous solution has been filed for approval with EMA for the treatment of alopecia areata, a debilitating autoimmune dermatological disease with intense psychological impact on all patients, especially in children.
Members of the Board
![](images/about/team/SAAD.png)
Saad Harti
CEO
Chairman
![](images/about/team/Geert.png)
Geert Cauwenbergh
PhD
Director
![](images/about/team/johan.png)
Johanne Barthelet
Director
Management Team
![](images/about/team/Jiawei.png)
Jiawei Liu
Head of R&D,
Drug Discovery
![](images/about/team/Michel.png)
Michel Chrétienne
PharmD
Director of Quality Pharmaceutical Development
![](images/about/team/Nadine.png)
Nadine Vincent
PharmD
Head of Regulatory Affairs
![](images/about/team/William.png)
Pr.William Pralong
MD PhD
Chief Scientific Officer
News & events
Oct 2023
Late-breaking news
&
Clinical data presentation
"EADV 2023"
Sept 2023
Broadcasted interview
"Legacy Healthcare
Botanical Drugs"
Jul 2023
Broadcasted interview
"Botanicals in pharma:
Potential and pitfalls"
Jan 2023
Press Release
"Positive Top-Line Results
from Phase 2/3 Trial"